Trofinetide

• CAT Number: I009894
• CAS Number: 853400-76-7
• Molecular Formula: C13H21N3O6
• Molecular Weight: 315.326
• Purity: ≥95%
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1
• InChIKey: BUSXWGRAOZQTEY-SDBXPKJASA-N
• SMILES: O=C(O)CC[C@@H](C(O)=O)NC([C@@]1(C)N(C(CN)=O)CCC1)=O

Trofinetide, also known as NNZ-2566, is a glypromate (or Gly-Pro-Glu) analog and neuroprotectant. NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury. NNZ-2566 demonstrates neuroprotective efficacy in models of traumatic brain injury. NNZ-2566 significantly decreases injury-induced upregulation of inflammatory cytokines including TNF-α, IFN-γ, and IL-6. NNZ-2566 is a potential therapeutic agent for fragile X syndrome.

Reference

1:Deacon RM, Glass L, Snape M, Hurley MJ, Altimiras FJ, Biekofsky RR, Cogram P. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Neuromolecular Med. 2015 Mar;17(1):71-82. doi: 10.1007/s12017-015-8341-2. Epub 2015 Jan 23. PubMed PMID: 25613838. 2:Cartagena CM, Phillips KL, Williams GL, Konopko M, Tortella FC, Dave JR, Schmid KE. Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3. Neuromolecular Med. 2013 Sep;15(3):504-14. doi: 10.1007/s12017-013-8236-z. Epub 2013 Jun 14. PubMed PMID: 23765588. 3:Wei HH, Lu XC, Shear DA, Waghray A, Yao C, Tortella FC, Dave JR. NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009 Aug 5;6:19. doi: 10.1186/1742-2094-6-19. PubMed PMID: 19656406; PubMed Central PMCID: PMC2731085.